Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.
about
Micro-RNAs and copy number changes: new levels of gene regulation in acute myeloid leukemiaDefining and Treating Older Adults with Acute Myeloid Leukemia Who Are Ineligible for Intensive TherapiesAn update of current treatments for adult acute myeloid leukemiaGenomics-based Approach and Prognostic Stratification Significance of Gene Mutations in Intermediate-risk Acute Myeloid LeukemiaStrategic applications of gene expression: from drug discovery/development to bedsideAllogeneic stem cell transplantation in first complete remissionMolecular prognostic factors in cytogenetically normal acute myeloid leukemiaCIViC databaseThe prognostic and functional role of microRNAs in acute myeloid leukemiaTET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia.Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemiaRUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.Distinct patterns of DNA damage response and apoptosis correlate with Jak/Stat and PI3kinase response profiles in human acute myelogenous leukemiaGAS6 expression identifies high-risk adult AML patients: potential implications for therapyAlternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a center for international blood and marrow transplant research-eurocord analysis.IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse.FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyDose escalation of lenalidomide in relapsed or refractory acute leukemias.BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.Functional pathway analysis using SCNP of FLT3 receptor pathway deregulation in AML provides prognostic information independent from mutational statusThe Prognostic Relevance of BAALC and ERG Expression Levels in Cytogenetically Normal Pediatric Acute Myeloid Leukemia.Expression and prognostic impact of lncRNAs in acute myeloid leukemia.Monoclonal antibodies against nucleophosmin mutants: potentials for the detection of acute myeloid leukemia.Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteriaAn intensive approach to treatment for older patients with relapsed isolated NPM1 mutated AML.Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemiaAssociation between DNMT3A mutations and prognosis of adults with de novo acute myeloid leukemia: a systematic review and meta-analysisPrognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report.Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia.High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia.Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemiaMitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia.Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia.Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemiaDynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapy
P2860
Q24612217-1B223DFE-E56C-4144-AFD3-412CCFBA2255Q26772235-5DE2F776-E668-4625-B81E-49A079A71757Q26776396-BDA48F96-2A4A-41CC-900B-7E6DE8884033Q26796514-90D6CB86-4E6B-4F56-843C-A1F62AFF0C45Q26864172-524DC970-3430-4B23-8A61-6FAFBC65B699Q26996818-4FF33A75-7F07-48B4-A4DD-6AE8D4804296Q26998811-57B4DE0E-5997-4BAB-8E04-E3B31228CA0AQ27612411-2D28DF22-08B4-40CB-9690-0B4F2074DF14Q27693865-4BD2002C-A84F-4EA4-A376-84FCFDB22074Q27851621-4EA2416E-905E-42DA-A26E-F07746125C26Q27851679-77A6A9FB-1ED5-4FBA-A754-9086A73EEEE6Q27851689-4FDA95A2-9659-4FF6-B7CF-1EC0736F2F71Q27851694-42D932A3-F7DA-421D-8D9C-37E67EA8D8CDQ27851713-9092ED57-CBEA-4A79-813F-F308FDF166E1Q27851839-8A561C22-A3F8-46A9-B7FC-3F3C48B8CAB6Q28749564-19517080-725B-444B-B21A-7B04B89BAB32Q33717707-D81EB7D8-FCAC-46BE-8EA7-CF024FCE7227Q33859061-21FDB069-B13B-4AC1-A10D-B1AB4F35BD13Q33897586-DDDD72C1-389A-4FC1-A6A3-0DB013111DB6Q34086334-80931DBB-C0FF-4A50-B982-6BB1FBF107C0Q34310561-ACC1A06F-A572-42E9-A44A-8AF85DBA67AEQ34488712-73303FD4-756D-4755-BE39-5A4C5E652548Q34541748-5763523B-B57C-4DF6-89AE-9EFB6EDF7BE6Q34595162-FAE3E220-EF1F-4DC3-AC93-23438ABDBBF9Q34766817-2BFB8B07-DB4A-4568-A01D-7C91298686F7Q34831106-ED6D57F6-1DE0-4136-8E3E-855B8861FD7AQ35001805-2768A294-B651-4A85-B13D-705F0AA50DEDQ35018521-7F1AE743-8A51-4B8C-99D7-108052714256Q35082370-90B46D0D-FF47-4601-88DE-5DE4F4841690Q35152173-D127B72E-CC15-43CF-A935-6BF67D8053CFQ35189447-83B9FDCA-0570-47CE-B009-2F074E4A7AE7Q35215042-9A68F55C-71D4-473A-B6A1-71742E87927FQ35265946-D8EFD137-3AAD-4AA8-81B7-B75767FD035DQ35596909-22521B16-3F91-491F-9DBF-C38248A29C24Q35741669-CF29FC41-3204-4E33-A4E5-A6F419433188Q35742564-F573C79E-3086-48E0-8C98-D886F6C8A921Q35781530-2E6BCABD-75A9-4A06-9033-2C23521C4E82Q35794120-45579CE0-CB94-4AF6-BF00-28C3D712836FQ35922032-99F5A15F-076F-4F57-8C47-591825AEC00AQ36065836-4E16504A-5FC0-4A80-8A5C-BD7B0CD9906E
P2860
Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Favorable prognostic impact of ...... er and Leukemia Group B study.
@ast
Favorable prognostic impact of ...... er and Leukemia Group B study.
@en
Favorable prognostic impact of ...... er and Leukemia Group B study.
@nl
type
label
Favorable prognostic impact of ...... er and Leukemia Group B study.
@ast
Favorable prognostic impact of ...... er and Leukemia Group B study.
@en
Favorable prognostic impact of ...... er and Leukemia Group B study.
@nl
altLabel
Favorable Prognostic Impact of ...... cer and Leukemia Group B Study
@en
prefLabel
Favorable prognostic impact of ...... er and Leukemia Group B study.
@ast
Favorable prognostic impact of ...... er and Leukemia Group B study.
@en
Favorable prognostic impact of ...... er and Leukemia Group B study.
@nl
P2093
P2860
P50
P921
P3181
P356
P1476
Favorable prognostic impact of ...... er and Leukemia Group B study.
@en
P2093
Andrew J Carroll
Bayard L Powell
Dean Margeson
Heiko Becker
Jonathan E Kolitz
Maria R Baer
Meir Wetzler
Michael A Caligiuri
Michael D Radmacher
Peter Paschka
P2860
P304
P3181
P356
10.1200/JCO.2009.25.1496
P407
P577
2010-02-01T00:00:00Z